Results 31 to 40 of about 14,647 (219)

Extremely Elevated International Normalized Ratio in a Patient with Dabigatran Etexilate Use. [PDF]

Cureus, 2019
Memon W, Aamir M, Memon A.
europepmc   +3 more sources

Dabigatran Etexilate: Management In Acute Ischemic Stroke

American Journal of Critical Care, 2013
A 54-year-old man treated with dabigatran experienced new onset of a stroke with a score of 9 on the National Institutes of Health Stroke Scale. Administration of recombinant tissue plasminogen activator (rtPA) was not recommended because of the dabigatran therapy.
Parisa P. Javedani, B. Zane Horowitz, Wayne M. Clark, Helmi L. Lutsep   +3 more
openalex   +4 more sources

A single-dose, four-cycle, fully repetitive crossover bioequivalence of dabigatran etexilate in Chinese. [PDF]

BMC Pharmacol Toxicol
Yang Z, Li Q, Yu D, Zhang X, Wang Y, Liu S, Chen L, Zhou Y, Zeng C, Zeng Y, Cai C, Xiong Y, Zhang Q, Li N, Du P, Liu L, Chen J, He Y.   +17 more
europepmc   +2 more sources

New options with dabigatran etexilate in anticoagulant therapy

Vascular Health and Risk Management, 2010
Lars Maegdefessel, Joshua M Spin, Junya Azuma, Philip S TsaoDepartment of Cardiovascular Medicine, Stanford University – School of Medicine, Stanford, CA, USAAbstract: Thrombosis, the localized clotting of blood, occurs in both the arterial and
Lars Maegdefessel, Joshua M Spin, Junya Azuma, et al   +3 more
doaj   +5 more sources

In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate. [PDF]

Sci Rep, 2018
Aljohani MM, Chinnappan R, Eissa S, Alsager OA, Weber K, Cialla-May D, Popp J, Zourob M.   +7 more
europepmc   +3 more sources

Stability of repackaged dabigatran etexilate capsules in dose administration aids. [PDF]

Eur J Hosp Pharm, 2018
Robertson SG, Glass BD.
europepmc   +3 more sources

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects

Pharmaceuticals, 2023
Higher risk of major hemorrhage associated with concomitant use of dabigatran and simvastatin compared to other statins was previously reported with a suggestion of P-glycoprotein-mediated interaction. The aim of this study was to evaluate the effects of
Hyewon Chung, Jong-Min Kim, Jin-Woo Park, Jihyeon Noh, Kyoung-Ah Kim, Ji-Young Park   +5 more
doaj   +1 more source

Pharmacokinetics and Pharmacogenetics of Dabigatran

Рациональная фармакотерапия в кардиологии, 2021
Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists.
A. V. Savinova, V. S. Dobrodeeva, M. M. Petrova, R. F. Nasyrova, N. A. Shnayder   +4 more
doaj   +1 more source

The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate

Drug Metabolism And Disposition, 2023
Dabigatran etexilate (DABE), a double ester prodrug of dabigatran, is a probe substrate of intestinal P-glycoprotein (P-gp) commonly used in clinical drug-drug interaction (DDI) studies.
Udomsak Udomnilobol, S. Jianmongkol, T. Prueksaritanont   +2 more
semanticscholar   +1 more source

EFFECT OF NON-SYNONYMOUS SINGLE-NUCLEOTIDE POLYMORPHISM OF HUMAN CARBOXYL ESTERASE 1 ON THE BIOACTIVATION OF DABIGATRAN ETEXILATE

International Journal of Applied Pharmaceutics, 2022
Objective: Dabigatran Etexilate is an oral acting direct thrombin inhibitor used for prophylaxis of cardioembolic events in non-valvular atrial fibrillation patients.
Goutham Yerrakula, S. George, K. D., A. P. R., J. N., S. Venkatachalam   +5 more
semanticscholar   +1 more source